PP3 theory test

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/102

encourage image

There's no tags or description

Looks like no tags are added yet.

Last updated 1:21 PM on 5/9/26
Name
Mastery
Learn
Test
Matching
Spaced
Call with Kai

No analytics yet

Send a link to your students to track their progress

103 Terms

1
New cards

Cannabis ingredients

CBD & THC

2
New cards

CBD is responsible for?

therapeutic effect

3
New cards

THC is responsible for?

Adverse effects

4
New cards

Max THC

less than 2% otherwise will be S8

5
New cards

CBD only products schedule?

S4

6
New cards

Ratio cbd vs thc

THC:CBD

7
New cards

Sativex

The only THC-containing good under TGA

8
New cards

Special access Scheme (SAS)

A regulatory pathway that allows patients to access unapproved therapeutic goods, including certain cannabis products, under specific conditions.

9
New cards

How do other TGA-containing products get recieved by patients

Must be SAS approved

10
New cards

When do prescribers need patient-specific authorisation

The patient is <18 yrs

Patient is drug dependent/serious substance-use disorder for drugs addiction in last 5 years

History of psychosis/psychiatric issue

Dose has >40mg of THC per day for oral, or 300mg per day for inhaled/vaporised products.

11
New cards

If no specific patient approval required?

No needed approval to prescribe

12
New cards

Cannabis can be dispensed?

at any pharmacy

13
New cards

Requirements on prescriptions for cannabis

same as S4/8

14
New cards

What does the wholesaler need before supplying cannabis

Copy of TGA approval from Pharmacy, and an approval from Office of Drug Control

15
New cards

Top of the TGA pyramid structure?

Executive

<p>Executive</p>
16
New cards

Second-line of the TGA pyramid structure?

3 divisions: Medicines Regulation division, Medical devices and product quality division, and regulatory Practice and Support Division

17
New cards

Role of Medication Regulation division

Monitioring medicines approved for supply in Aus.

18
New cards

Branches under Medicines Regulation (TGA)

OTC and complementary meds, Pharmacovigilance and SAS (Vaccines, unapproved in Australia meds from overseas etc), Prescription Medicines and Authorisation Branch, and the Scientific Evaluation (provides scientific advice about the medicines, guiding on how to regulate them).

19
New cards

Medical Devices and Product Quality Division (TGA)

Regulation of medical devices, quality assurance, compliance and safety monitoring, and pre-market evaluation.

20
New cards

Branches under Medical Devices and Product Quality Division (TGA)

Laboratories Branch (Labs for quality assesment and procedures to make meds), manufacturing quality (ensuring manufacturers meet quality standards), and medical devices (ensuring quality of med devices).

21
New cards

Regulatory Practice and Support Division (TGA)

Provides guidance on regulatory practices, supports compliance, and facilitates communication with stakeholders in the therapeutic goods sector.

22
New cards

Branches of Regulatory Practice and Support Division (TGA)

Regulatory engagement and planning branch (media responses, communications planning, and stakeholder engagement), Regaulatory practice, education and compliance (oversight of compliance with regulations), and guidance and policy branch (developing regulatory guidance and policy frameworks, supports the rest of the TGA structure).

23
New cards

Statutary Advisory Comittees

Statutory advisory committees on Biologicals, on Chemical Scheduling, and on complementary medicines

24
New cards

Statutory advisory committees on Biologicals (ACB)

Advice + recommendation on cell and tissue products

25
New cards

Statutary Advisory Comittee on Chemical Scheduling (ACCS)

Advice + Recommendations on how chemicals should be made available to the public (scheduling of chemicals and not meds?).

26
New cards

Statutary Advisory Comittee on Complementary meds

Advice + recommendations on entering natural meds on the ARTG (refer to other flashcard for this definition). Advice and recommendations

27
New cards

Statutary Advisory Comittee med devices

Advice + recommendations on safety + perfomance of med devices

28
New cards

Statutary Advisory Comittee on meds

Advice + recommendations on entering meds into ARTG

29
New cards

Statutary Advisory Comittee on med schedulling

Advice + recommendations on how to make meds available to public (SUSMP came form this committee :/).

30
New cards

Statutary Advisory Comittee on vaccines

Advice + recommendations n safety, efficacy, quality of vaccines.

31
New cards

Australian Register of Therapeutic Goods (ARTG)

No product/med device that claims a therapeutic effect can be supplied in Aus without being registered on this register.

32
New cards

Name 2 things not regulated by TGA

Food and cosmetics (as they don’t claim therapeutic effect).

33
New cards

What aspects of therapeutic goods does the TGA regulate?

Manufacturing, supplying, imports and and Advertising of TGs.

34
New cards

Bet u didn’t know that the TGA also regulates

Anything used in the manufacture of drugs (other ingredients), and also anything to replace/modify parts of anatomy (surgery-ish prooducts/tools)

35
New cards

Med definition

Used on human or animal to achieve/likely to achieve, a therapeutic goal through pharmacological/metabolic/chemical/etc means.

36
New cards

Medical devices

Defined as being used on ONLY humans and must have a therapeutic BENEFIT (not effect). physical or mechanical effect on the body (including anything from bandages, to MRI scanners, to artificial body parts etc).

37
New cards

How to know if a product is to be considered a food or medicine?

Will depend on the claims it has. If it claims to have therapeautic effect —> medicine.

38
New cards

How to know if a product is to be considered a cosmetic or medicine?

Mainly depends on route of admin, ingredients, and claim on label/ad (If it claims to have therapeautic effect —> med. e.g., moisturiser claims to protect against UV due to sunscreen agent = med.)

39
New cards

Therapeutics Goods Act 1989 applies to who?

Sponsors: anyone who exports/imports meds, or who manufactures or has them imported/manufactured on their behalf. Includes authorities + hospitals and anyone involved in the provision of PBS/RPBS items.

40
New cards

Difference in assessing high-risk and low-risk meds

High risk is assessed for safety, quality and efficacy whereas low-risk is assessed for safety and quality only

41
New cards

Outer packaging TGA code

AUST L/AUST R on outer packaging indicates that it has been approved by TGA and is available for supply.

42
New cards

Meds and medical devices are classifies based on?

their risk level

43
New cards

Other things the TGA regulates

 In vitro diagnostic medical devices (IVDs)

 blood

 blood components

 plasma derivatives

 tissue and cellular products

 tissue and cell based derivatives

 sterilants and disinfectants

44
New cards

Whether a medicine is listed on the ARTG or Registered on the ARTG depends on?

  • Ingredients

  • Dosage form

  • The claims of the therapeutic effect of the product

45
New cards

Listed meds on ARTG

lower risk, only have ingredients that are well-known + unschedulled, usually self-selected by consumers, not assessed for efficacy, all sponsers must hold evidence for the listed product’s claims, must have an AUST L on packaging. e.g. herbal/complementary, sunscreens etc.

46
New cards

ALL exported meds are registered or listed?

Listed, imported ones can be either i think?

47
New cards

Registered meds on ARTG

Higher risk, assessed rigourously on safety, eficacy and quality. Must have an AUST R on packaging, can be categroised into high/low risk.

48
New cards

Categories of resitered meds on ARTG

Non-prescription (low-risk) and prescription (high-risk)

49
New cards

Non-prescription registered meds on ARTG

OTC & complementary, No S4, 8 or 9 ingredients. Usually contains ingredients from S2 and 3 and sometimes 5 & 6. Non-prescription meds.

50
New cards

Prescription registered meds on ARTG

May include ingredients of S4, 8 & S9. prescription meds.

51
New cards

Can complementary meds be registered?

YES! Depends on claims in the product. If claims to cure, prevent, alleviate or diagnose —> are a TG.

52
New cards

What meds are excluded from the TG Act 1989

Porducts (usually devices) that unintentionally come under TG definition. They are therefore excluded because it wasn’t on purpose.

53
New cards

What products are exempt?

Products that aren’t on the ARTG (not listed or registered) because of a specific exemption. Usually, these products pose little risk to the public. Must still comply with other TGA standards and regulations, including advertising and labelling.

54
New cards

Products can be exempt from what? (under the TGA)

ARTG or from ARTG AND Manufacturing requirements. These are neither listed or registered under the ARTG.

55
New cards

Can exemptions be revoked?

YES!

56
New cards

What is an unapproved drug?

A drug that is not classified as listed or registered or exempted on the ARTG.

57
New cards

Access to unapproved Drugs

Authorised prescriber, SAS, personal importation scheme, or participating clinical trial.

58
New cards

Must an approved prescriber (to supply unapproved drugs) report to TGA when supplying?

No, but must submit a record of all treated individuals every 6 months.

59
New cards

Category A of patients under the SAS scheme

Patient is seriously ill —> prescriber gives out unapproved drug—> must complete Category Approval to Supply form and submit within 28 days to the TGA nd supplier. TGA does not reply though. Only for medical practitioners. Suppliers cannot supply without form.

60
New cards

Category B of patients under the SAS scheme

Patients that don’t fit category A or C (no history of using the Unapproved Drug). The prescriber fills out the Category B form (or document with same info), preferably with handwriting. Usually prescribers are dental or medical. TGA must reply for approval before supply.

61
New cards

Category C of patients under the SAS scheme

Patients with a history of using the unapproved drug. The prescriber must complete the Category C form and submit it to the TGA. TGA does not reply, and supply can occur after submission. Can be meds, med devices or biologicals. There is a list available for the products and their indications, as well as the prescribers that can apply. The drug being on that list acts as the approval for the supplier to supply.

62
New cards

Personalised Importation scheme

Brought a med with you from overseas, or imported it within Australia from overseas. Must be for you or immediate family members. Order as much as you want of the drug within a 12-month period at max dose recommended by manufacturer, but cannot exceed 15 month supply. Can’t be an illegal drug, or have human/animal remains. If it’s a S4 or S8, must have a prescription from authorised prescriber. Want more supply than 15 month? Doctor must apply from permission under SAS.

63
New cards

Manufacturing (TGA definition)

Producing goods or being involved in the process of producing goods

64
New cards

Good manufacturing Practice guidelines

Describe the principles and practices that are necessary to follow in order to provide assurance that each batch of a therapeutic good is safe, reliable, and of consistent high quality. Manufacturers must hold a licence and also their factory must meet GMP guidleines via audits

65
New cards

GMP guidelines not met?

License can be revoked, TGA officer can walk in anytime. Refusal to give samples for testing = fine.

66
New cards

compounded medicines must meet GMP guidelines?

No, they are exempt from requiring manufacturing licences. But encouraged to meet guidelines anway. But compounded goods for sale on large scale = pharmacist must apply to TGA for license.

67
New cards

Advertising restriction

OTC = allowed most of the time.

Prescription and some pharmacist-only meds = prohibited to make ads abt them

68
New cards

Advertising prescription-only

Not allowed to consumers

Allowed to healthcare professionals under self-regulatory scheme operated by Medicines Australia

Also must meet the Competition and consumers Act

69
New cards

Schedule 3

Some may be advertised to consumers, not all.

70
New cards

Non-prescription ads

Ok mostly. Regulated by both self-regulatory and co-regulatory arrangements.

71
New cards

Ads that require approval

TV, Cinema, Radio, outdoors (billboards, etc.), and print media (magazines, newsapapers).

72
New cards

Medical devices

A similar regulation to non-prescription; however, no prior approval needed.

73
New cards

AD regulations

Must be realistic of effectiveness, not unwarranted, and have no incorrect or unbalanced statements.

Mustnt lead consumers to self-diagnosing or inappropriate treatment

No taking advantage of lack of knowledge of consumers.

Musnt encourage inappropriate/excessive use.

Must not claim it has no side effects

No ads towards minors

No personal incentives in the ad

Cannot say it is recommended by an authoritative body (like TGA/governemnt etc).

74
New cards

Who do the advertising regulations not apply to?

These regualtions do not apply when advertising to most healthcare professionals

Don’t apply to non-human use meds.

75
New cards

What must an AD contain

The drug name, the indication, the dose form, and trade name.

Also USE ONLY AS DIRECTED SEE DOCTOR IF SYMPTOMS PERSIST

ASK YOUR PHARMACIST

ALWAYS READ THE LABEL

76
New cards

No ads for:

unlisted, unregistered, and non-exempted (unapproved drugs).

77
New cards

Recalling is responsibility of?

Sponspor that caused the fault to recall.

78
New cards

Recalling classifications

  • Class 1 - Life-threatening or serious risk to health

  • Class 2 - can cause defect or mistreatment, not as risky as Class 1

  • Class 3 – no risk to health, but recalled for other reasons.

79
New cards

stages of recall

  1. notify the coordinator of crisi management

  2. collect info to conduct assessment

  3. assess the recall

  4. recall

  5. notify federal minister of Consumer Affairs

  6. conclude recall and report

  7. follow-up actions

80
New cards

Bioequivalent

same mechnaism of action + absorption.

81
New cards

Generics

Bioequivalent to the brand product, it may or may not be more expensive. Made because the brand product is not protected by patent. Allows for brand substitution.

82
New cards

Generic vs Brand

Same absorption and MOA, same strength and quantity, but different excipients. Can be switched to/from generic by a pharmacist or prescriber.

83
New cards

Substitutes in the Schedules of Pharmaceutical Benefits,

Flagged with an "a". These brands can be interchanged without any clinical effect. Anything flagged like this can be substituted by the pharmacist.

84
New cards

Biosimiliar

Highly similiar biological drug to already existing biological drug. Not identicle.

85
New cards

Interchangeability

Can only be changed by the prescriber. Drugs that are interchangeable (often of the same class).

86
New cards

Marked “b” on schedule of pharmaceutical benefits

We don’t know if they’re bioequivalent to the brands marked "a".

87
New cards

What if there is no brand on prescription?

Pick up anything flagged “a,” that is biosimiliar or equivalent. No need to notify prescriber.

88
New cards

The patient wants a brand when “brand substitution is not permitted” on the prescription.

No option for patient. Discuss with prescriber.

89
New cards

When is substitution not allowed?

When brands are not bioequivalent

Medicines with narrow therapeutic index (e.g. epeliptic meds). Seek prescriber advice first

Risk of confusion anxiety/harm

Negative impact on adherence

Allergy/intolerance/concern to excipients

Different device used to admin med

90
New cards

Why are biosimilars not identical?

Bcause they are made from biological cells —> making an identical is impossible, as they are very complex

91
New cards

Drug-Related Problem (DRP)

A medication-related issue that can potentially harm a patient or prevent optimal pharmacotherapy. This includes issues like adverse drug reactions, drug interactions, or inappropriate medication use.

92
New cards

Clincial Interventions

It involves identifying current/potential DRPs and changing patient drug therapy.

93
New cards

SOAP

Subjective info, objective info, assess the info collected (S & O) and plan

94
New cards

Clinical problem solving framework

Collect info, Identify problem (DRP), and then Resolve DRPs.

95
New cards

Problem-solving

Nature of problem, its consequence, and plan to manage it

96
New cards

Identifying DRPs

  1. Identify the drug

  2. Identify indications for each med

  3. Dose/s prescribed

  4. Drug-drug Interaction

  5. Drug-disease interactions

97
New cards

8 categroies of DRPs

  1. Drug selection

  2. Over/underuse

  3. Compliance

  4. Undertreated

  5. Monitoring

  6. Education

  7. Not classifiable

  8. Adverse effects/toxicity

98
New cards

My health record

Record of medical history, medications, Procedures the patient underwent available to Health professionals 24/7. All Australians have one/an individual healthcare identifier.

99
New cards

Safe to assume MHRa is thorough?

Nope. The patient has control over what you see. They may have deleted some information or requested restrictions. Never safe to assume that.

100
New cards

Can a healthcare professional access MHR without the patient being present?

Yes!